Biovica International AB – Annual Report for the fiscal year 2019/2020 published
Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com.hemsida.eu/investor-relations/financials/
Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com.hemsida.eu/investor-relations/financials/
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Cecilia Driving, EVP CFO/HR/IR
Phone +46-73-125 92 47
E-mail: cecilia.driving@biovica.com
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica’s vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica’s shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company’s Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.